Tech Company Financing Transactions
Carisma Therapeutics Funding Round
On 3/2/2021, Carisma Therapeutics raised $59 million in Series B funding from 4BIO Capital, IP Group and Penn Medicine.
Transaction Overview
Company Name
Announced On
3/2/2021
Transaction Type
Venture Equity
Amount
$59,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance current pipeline and discovery programs, including the Phase I clinical trial of CARISMA's lead candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage discovered at the University of Pennsylvania (Penn).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3675 Market St. 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Undisclosed
Website
Email Address
Overview
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Kelly
Chief Medical Officer
Debora Barton
Chief Technical Officer
Daniel Cushing
VP - Bus. Development
Thomas Wilton
VP - R & D
Michael Klichinsky
Browse more venture capital transactions:
Prev: 3/2/2021: Skydio venture capital transaction
Next: 3/2/2021: FogPharma venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs